Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript
Company Participants
Joshua Higa – Director of Investor Relations & Corporate Communications
Emil Kakkis – Founder, President, CEO & Director
Erik Harris – Executive VP & Chief Commercial Officer
Howard Horn – Executive VP of Corporate Strategy & CFO
Eric Crombez – Chief Medical Officer & Executive VP
Conference Call Participants
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Yaron Werber – TD Cowen, Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Eliana Merle – Barclays Bank PLC, Research Division
Anupam Rama – JPMorgan Chase & Co, Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
Allison Bratzel – Piper Sandler & Co., Research Division
Maxwell Skor – Morgan Stanley, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Benjamin Burnett – Wells Fargo Securities, LLC, Research Division
Lydia Erdman – Goldman Sachs Group, Inc., Research Division
Shelby Hill – RBC Capital Markets, Research Division
Wing Yip – Wedbush Securities Inc., Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Amit Dayal – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good afternoon and welcome to the Ultragenyx Second Quarter 2026 Financial Results Conference Call.
[Operator Instructions]
It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations.
Joshua Higa
Director of Investor Relations & Corporate Communications
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Howard Horn, Chief Financial Officer; Erik Harris, Chief Commercial Officer; and Eric Crombez, Chief Medical Officer.
I’d like to remind everyone that during today’s call, we will be making forward-looking statements. These statements are subject to certain risks
